These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 376458)

  • 21. Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients.
    Conard GJ; Cronheim GE; Klempt HW
    Arzneimittelforschung; 1982; 32(2):155-9. PubMed ID: 7199921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Lorcainid--electrophysiologic examinations of a new anti-arrhythmia agent].
    Gstöttner M; Ng CK; Gmeiner R
    Acta Med Austriaca; 1978; 5(4-5):137-8. PubMed ID: 756123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration.
    Chay S; Woods WE; Rowse K; Nugent TE; Blake JW; Tobin T
    Drug Metab Dispos; 1983; 11(3):226-31. PubMed ID: 6135581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans.
    Conard GJ; Carlson GL; Frost JW; Ober RE; Leon AS; Hunninghake DB
    Clin Ther; 1984; 6(5):643-52. PubMed ID: 6478470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
    Boothe DM; Perkins J
    J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic studies of quinidine in patients with arrhythmias.
    Conrad KA; Molk BL; Chidsey CA
    Circulation; 1977 Jan; 55(1):1-7. PubMed ID: 830196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lorcainide. I. Saturable presystemic elimination.
    Jähnchen E; Bechtold H; Kasper W; Kersting F; Just H; Heykants J; Meinertz T
    Clin Pharmacol Ther; 1979 Aug; 26(2):187-95. PubMed ID: 455887
    [No Abstract]   [Full Text] [Related]  

  • 28. The disposition and metabolic fate of 14C-cibenzoline in man.
    Massarella JW; Loh AC; Williams TH; Szuna AJ; Sandor D; Bressler R; Leinweber FJ
    Drug Metab Dispos; 1986; 14(1):59-64. PubMed ID: 2868867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Flecainide: a new antiarrhythmic agent].
    Leclercq JF; Coumel P
    Arch Mal Coeur Vaiss; 1983 Oct; 76(10):1218-30. PubMed ID: 6418100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and efficacy of pirmenol hydrochloride in the treatment of ventricular dysrhythmia.
    Lee TG; Goldberg AD; Chang T; Serkland MT; Yakatan GJ; Johnson EL; Toole JG; Goldstein S
    J Cardiovasc Pharmacol; 1983; 5(4):632-7. PubMed ID: 6193362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial clinical experience of lorcainide (Ro 13-1042), a new antiarrhythmic agent.
    Cocco G; Strozzi C
    Eur J Clin Pharmacol; 1978 Nov; 14(2):105-9. PubMed ID: 363430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Eiriksson Ce; Brogden RN
    Drugs; 1984 Apr; 27(4):279-300. PubMed ID: 6373222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lorcainide for high-frequency ventricular arrhythmia: preliminary results of a short-term double-blind and placebo-controlled crossover study and long-term follow-up.
    Singh SN; DiBianco R; Kostroff LI; Fletcher RD; Cockrell JL
    Am J Cardiol; 1984 Aug; 54(4):22B-28B. PubMed ID: 6380261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistant ventricular arrhythmias treated with lorcainide, a new antiarrhythmic drug.
    Somani P; di Giorgi S
    Chest; 1980 Oct; 78(4):658-60. PubMed ID: 7418495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of intravenous lorcainide with lidocaine for acute therapy of complex ventricular arrhythmias: results of a randomized study with crossover option.
    Anderson JL; Anastasiou-Nana M; Lutz JR; Writer SL
    J Am Coll Cardiol; 1985 Feb; 5(2 Pt 1):333-41. PubMed ID: 3881497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Propafenone disposition kinetics in cardiac arrhythmia.
    Connolly S; Lebsack C; Winkle RA; Harrison DC; Kates RE
    Clin Pharmacol Ther; 1984 Aug; 36(2):163-8. PubMed ID: 6744775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flecainide: a new agent for the treatment of ventricular arrhythmias.
    Grubb BP; Tilley-Gray B
    Am J Med Sci; 1986 Sep; 292(3):160-3. PubMed ID: 3529958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lorcainide (R 15 889), a first review.
    Amery WK; Heykants JJ; Xhonneux R; Towse G; Oettel P; Gough DA; Janssen PA
    Acta Cardiol; 1981; 36(3):207-34. PubMed ID: 7020313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcainide antiarrhythmic effect.
    Mead RH; Keefe DL; Kates RE; Winkle RA
    Am J Cardiol; 1985 Jan; 55(1):72-8. PubMed ID: 2578245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.